Literature DB >> 18200579

Development of multiple complications in type 2 diabetes is associated with the increase of multiple markers of chronic inflammation.

Jawl-Shan Hwang1, Tsu-Lan Wu, S C Chou, C Ho, Pi-Yueh Chang, Kuo-Chien Tsao, Jeng-Yi Huang, Chien-Feng Sun, James T Wu.   

Abstract

Patients with type 2 diabetes (T2DM) are known at risk for developing cardiovascular disease (CVD), nephropathy, and cancer. We were interested to find out whether multiple markers associated with chronic inflammation are detectable in patients with T2DM and are increased in patients with T2DM who developed additional clinical complications. A sequence of multiple risk markers for atherogenesis, associated with chronic inflammation, was measured in patients with T2DM before and after the development of clinical complications. We found that multiple clinical complications frequently developed simultaneously in patients with T2DM. At the early stage of T2DM, only low levels and low percent elevations of multiple risk markers were detected. However, both the level and the percent elevation of these markers were found to increase with disease progression and the development of clinical complications. We believe that chronic inflammation not only contributes to the pathogenesis of T2DM but also continues to increase in T2DM patients who are developing additional clinical complications. It appears that these multiple markers are potentially useful not only for monitoring the progression of T2DM but also predicting the risk of developing macro- and microvascular disease, nephropathy, and cancer. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18200579      PMCID: PMC6649190          DOI: 10.1002/jcla.20207

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  31 in total

1.  Development of a microplate ELISA for circulating E-selectin: assay characterization, comparison with a commercial kit, wand establishment of normal reference values.

Authors:  Kuo-Chien Tsao; Pi-Yueh Chang; Chia-Chi Li; Tsu-Lan Wu; Chien-Feng Sun; James T Wu
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

Review 2.  Inflammation as a cardiovascular risk factor.

Authors:  James T Willerson; Paul M Ridker
Journal:  Circulation       Date:  2004-06-01       Impact factor: 29.690

Review 3.  Acute-phase proteins and other systemic responses to inflammation.

Authors:  C Gabay; I Kushner
Journal:  N Engl J Med       Date:  1999-02-11       Impact factor: 91.245

4.  Targeting C-reactive protein for the treatment of cardiovascular disease.

Authors:  Mark B Pepys; Gideon M Hirschfield; Glenys A Tennent; J Ruth Gallimore; Melvyn C Kahan; Vittorio Bellotti; Philip N Hawkins; Rebecca M Myers; Martin D Smith; Alessandra Polara; Alexander J A Cobb; Steven V Ley; J Andrew Aquilina; Carol V Robinson; Isam Sharif; Gillian A Gray; Caroline A Sabin; Michelle C Jenvey; Simon E Kolstoe; Darren Thompson; Stephen P Wood
Journal:  Nature       Date:  2006-04-27       Impact factor: 49.962

Review 5.  Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease.

Authors:  John Kanellis; Duk-Hee Kang
Journal:  Semin Nephrol       Date:  2005-01       Impact factor: 5.299

Review 6.  Chronic systemic inflammation in dialysis patients: an update on causes and consequences.

Authors:  Qiang Yao; Jonas Axelsson; Peter Stenvinkel; Bengt Lindholm
Journal:  ASAIO J       Date:  2004 Nov-Dec       Impact factor: 2.872

7.  Microplate ELISA for urine microalbumin: reference values and results in patients with type 2 diabetes and cardiovascular disease.

Authors:  Tsu-Lan Wu; Pi-yueh Chang; Chia-Chi Li; Kuo-Chien Tsao; Chien-Feng Sun; James T Wu
Journal:  Ann Clin Lab Sci       Date:  2005       Impact factor: 1.256

8.  Enzymatic assay of homocysteine on microtiter plates or a TECAN analyzer using crude lysate containing recombinant methionine gamma-lyase.

Authors:  Err-Cheng Chan; Pi-Yueh Chang; Tsu-Lan Wu; James T Wu
Journal:  Ann Clin Lab Sci       Date:  2005       Impact factor: 1.256

9.  Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes.

Authors:  E S Leinonen; A Hiukka; E Hurt-Camejo; O Wiklund; S S Sarna; L Mattson Hultén; J Westerbacka; R M Salonen; J T Salonen; M-R Taskinen
Journal:  J Intern Med       Date:  2004-08       Impact factor: 8.989

10.  Uric acid in chronic heart failure: a marker of chronic inflammation.

Authors:  F Leyva; S D Anker; I F Godsland; M Teixeira; P G Hellewell; W J Kox; P A Poole-Wilson; A J Coats
Journal:  Eur Heart J       Date:  1998-12       Impact factor: 29.983

View more
  2 in total

1.  The effect of aerobic versus strength-based training on high-sensitivity C-reactive protein in older adults.

Authors:  Raul A Martins; Ana P Neves; Manuel J Coelho-Silva; Manuel T Veríssimo; Ana Maria Teixeira
Journal:  Eur J Appl Physiol       Date:  2010-05-01       Impact factor: 3.078

2.  Insight in modulation of inflammation in response to diclofenac intervention: a human intervention study.

Authors:  Marjan J van Erk; Suzan Wopereis; Carina Rubingh; Trinette van Vliet; Elwin Verheij; Nicole H P Cnubben; Theresa L Pedersen; John W Newman; Age K Smilde; Jan van der Greef; Henk F J Hendriks; Ben van Ommen
Journal:  BMC Med Genomics       Date:  2010-02-23       Impact factor: 3.063

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.